BRT Apartments GAAP EPS of -$0.14, revenue of $23.7M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2025
0mins
Should l Buy BRT?
Source: SeekingAlpha
Financial Performance: BRT Apartments reported a Q2 GAAP EPS of -$0.14 and revenue of $23.7 million, reflecting a slight decline of 0.3% year-over-year.
Rating Status: Seeking Alpha's Quant Rating indicates that BRT Apartments has not received an upgrade despite the release of historical earnings data and a dividend scorecard.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRT
Wall Street analysts forecast BRT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.540
Low
20.00
Averages
20.00
High
20.00
Current: 14.540
Low
20.00
Averages
20.00
High
20.00
About BRT
BRT Apartments Corp. is a real estate investment trust that owns, operates, and to a lesser extent, holds interest in joint ventures that own and operate multifamily properties. The Company owns or has interests in over 31 multifamily properties with 8,311units in 11 states and has preferred equity investments in two multi-family properties. Generally, its multifamily properties are garden apartments and, to a lesser extent, mid-rise or town home style properties that provide residents with amenities, such as a clubhouse, swimming pool, laundry facilities and Internet access. In addition to its multifamily properties and preferred loan investments, the Company owns assets, and in particular, real estate assets. Its properties include Silvana Oaks Apartments, Avondale Station, Brixworth at Bridge Street, Newbridge Commons, Crossings of Bellevue, Avalon Apartments, Parkway Grande, Woodland Trails, Grove at River Place, Kilburn Crossing, The Woodland Apartments, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bioretec Secures CMS TPT Status for RemeOs™ Trauma Screw, Setting New Orthopedic Standard
- Innovative Payment Mechanism: Bioretec's RemeOs™ Trauma Screw received Transitional Pass-Through Payment (TPT) status from CMS effective October 1, 2025, aimed at reducing the cost burden on hospitals and surgical centers for adopting new technologies, thereby enhancing patient access to innovative orthopedic implants.
- Code Revision Impact: Effective January 1, 2026, the HCPCS code C1741's descriptor was updated to “absorbable metallic bone fixation anchor/screw,” explicitly focusing on absorbable metallic implants, aligning with FDA regulatory classifications and further solidifying Bioretec's market leadership.
- Market Uniqueness: RemeOs™ is the only osteopromotive absorbable metal implant approved in the U.S., designed to support bone healing while gradually degrading and being replaced by native bone, thus reducing long-term risks and costs associated with permanent metallic implants, showcasing its innovative potential in orthopedics.
- Regulatory Recognition: The TPT status aligns with the FDA's Breakthrough Device Designation and De Novo market authorization granted in March 2023, highlighting Bioretec's clinical and economic value in absorbable metal technology, further enhancing its competitiveness in the global market.
See More
Bioretec Schedules 2026 Financial Reports and Annual General Meeting
- Financial Reporting Schedule: Bioretec plans to publish its financial reports in 2025, with all reports available through company releases and on its website, ensuring timely access to key information for investors and enhancing transparency.
- Annual General Meeting Date: The company has scheduled its Annual General Meeting for May 8, 2026, with the Board of Directors to provide further details later, aiming to strengthen communication and engagement with shareholders.
- Innovative Product Line: Bioretec's RemeOs™ product line received market authorization in the U.S. in March 2023 and CE mark approval in Europe in January 2025, marking a technological breakthrough in biodegradable implants that is expected to drive future sales growth.
- Global Market Presence: Bioretec's products are utilized in approximately 40 countries, showcasing its influence and market potential in the global orthopedic medical market, further solidifying its leadership position in the industry.
See More
Bioretec Schedules 2026 Financial Reports and Annual General Meeting
- Financial Reporting Schedule: Bioretec plans to publish multiple financial reports in 2025, with all reports being made available through company releases on its website, ensuring timely access to key information for investors.
- Annual General Meeting Date: The company has scheduled its Annual General Meeting for May 8, 2026, with the Board of Directors to provide further details, reflecting the company's commitment to shareholder communication.
- Innovative Product Line: Bioretec's RemeOs™ product line received market authorization in the U.S. in March 2023 and CE mark approval in Europe in January 2025, marking a technological breakthrough in biodegradable implants that is expected to drive future sales growth.
- Global Market Presence: Bioretec's products are utilized in approximately 40 countries, demonstrating its extensive influence and market penetration in the global orthopedic medical market.
See More
BRT Apartments Corp. Successfully Refinances $42.7 Million in Mortgages
- Successful Refinancing: BRT Apartments Corp. has successfully refinanced three maturing mortgages totaling $42.7 million, with new mortgage debt amounting to approximately $71.9 million, resulting in an increase in the weighted average interest rate from 4.36% to 4.95%, thereby strengthening its financial foundation for future investments.
- Enhanced Financial Flexibility: The refinancing allowed BRT to use $17.5 million of the proceeds to pay off the outstanding balance of its credit facility, enhancing the company's financial flexibility and positioning it to seize future investment opportunities in its core Sunbelt markets.
- Long-Term Value Focus: CEO Jeffrey A. Gould emphasized that the company will continue to focus on value-enhancing opportunities aimed at driving substantial long-term shareholder value, reflecting confidence in the potential of future market opportunities.
- Diversified Portfolio: As of December 17, 2025, BRT owns or has interests in 31 multi-family properties with 8,311 units, demonstrating its ongoing expansion in diversified investments and market coverage.
See More
BRT Apartments Corp. Finalizes Debt Refinancing Deals
Refinancing Details: BRT Apartments Corp. has refinanced three maturing mortgages totaling $42.7 million, replacing them with new debt of approximately $71.9 million at a higher interest rate of 4.95% and a remaining term of about nine years.
Financial Strategy: The company utilized $17.5 million from the refinancing proceeds to pay off its credit facility, positioning itself to pursue future investment opportunities in core Sunbelt markets.
Company Overview: BRT is a real estate investment trust that owns and operates multi-family properties, currently holding interests in 31 properties with a total of 8,311 units across 11 states.
Leadership Statement: CEO Jeffrey A. Gould emphasized the company's focus on value-enhancing opportunities to drive long-term shareholder value following the successful refinancing.
See More
Bioretec Updates Strategy for 2026-2028 with New Financial Targets
- Strategic Overhaul: Bioretec's strategy for 2026-2028 focuses on commercial performance and sales acceleration in both the U.S. and international markets, aiming for growth through ongoing R&D and expansion of the RemeOs™ product family.
- Innovation-Driven: The company is committed to establishing a competitive advantage through leading materials science and clinical evidence generation, with the goal of becoming a recognized player in the global orthopedic market, particularly in absorbable metal implants by the end of the strategy period.
- Financial Targets: Despite planned strategic investments in R&D and commercialization, Bioretec does not expect to achieve cash flow positivity or profitability during this period, indicating a focus on long-term growth.
- Pipeline Update: Bioretec plans to introduce a new product every 12-18 months, particularly expanding the RemeOs™ product family to meet market demand for high-performance absorbable implants, further solidifying its market position.
See More
Bioretec Secures CMS TPT Status for RemeOs™ Trauma Screw, Setting New Orthopedic Standard
- Innovative Payment Mechanism: Bioretec's RemeOs™ Trauma Screw received Transitional Pass-Through Payment (TPT) status from CMS effective October 1, 2025, aimed at reducing the cost burden on hospitals and surgical centers for adopting new technologies, thereby enhancing patient access to innovative orthopedic implants.
- Code Revision Impact: Effective January 1, 2026, the HCPCS code C1741's descriptor was updated to “absorbable metallic bone fixation anchor/screw,” explicitly focusing on absorbable metallic implants, aligning with FDA regulatory classifications and further solidifying Bioretec's market leadership.
- Market Uniqueness: RemeOs™ is the only osteopromotive absorbable metal implant approved in the U.S., designed to support bone healing while gradually degrading and being replaced by native bone, thus reducing long-term risks and costs associated with permanent metallic implants, showcasing its innovative potential in orthopedics.
- Regulatory Recognition: The TPT status aligns with the FDA's Breakthrough Device Designation and De Novo market authorization granted in March 2023, highlighting Bioretec's clinical and economic value in absorbable metal technology, further enhancing its competitiveness in the global market.
See More
Bioretec Schedules 2026 Financial Reports and Annual General Meeting
- Financial Reporting Schedule: Bioretec plans to publish its financial reports in 2025, with all reports available through company releases and on its website, ensuring timely access to key information for investors and enhancing transparency.
- Annual General Meeting Date: The company has scheduled its Annual General Meeting for May 8, 2026, with the Board of Directors to provide further details later, aiming to strengthen communication and engagement with shareholders.
- Innovative Product Line: Bioretec's RemeOs™ product line received market authorization in the U.S. in March 2023 and CE mark approval in Europe in January 2025, marking a technological breakthrough in biodegradable implants that is expected to drive future sales growth.
- Global Market Presence: Bioretec's products are utilized in approximately 40 countries, showcasing its influence and market potential in the global orthopedic medical market, further solidifying its leadership position in the industry.
See More
Bioretec Schedules 2026 Financial Reports and Annual General Meeting
- Financial Reporting Schedule: Bioretec plans to publish multiple financial reports in 2025, with all reports being made available through company releases on its website, ensuring timely access to key information for investors.
- Annual General Meeting Date: The company has scheduled its Annual General Meeting for May 8, 2026, with the Board of Directors to provide further details, reflecting the company's commitment to shareholder communication.
- Innovative Product Line: Bioretec's RemeOs™ product line received market authorization in the U.S. in March 2023 and CE mark approval in Europe in January 2025, marking a technological breakthrough in biodegradable implants that is expected to drive future sales growth.
- Global Market Presence: Bioretec's products are utilized in approximately 40 countries, demonstrating its extensive influence and market penetration in the global orthopedic medical market.
See More
BRT Apartments Corp. Successfully Refinances $42.7 Million in Mortgages
- Successful Refinancing: BRT Apartments Corp. has successfully refinanced three maturing mortgages totaling $42.7 million, with new mortgage debt amounting to approximately $71.9 million, resulting in an increase in the weighted average interest rate from 4.36% to 4.95%, thereby strengthening its financial foundation for future investments.
- Enhanced Financial Flexibility: The refinancing allowed BRT to use $17.5 million of the proceeds to pay off the outstanding balance of its credit facility, enhancing the company's financial flexibility and positioning it to seize future investment opportunities in its core Sunbelt markets.
- Long-Term Value Focus: CEO Jeffrey A. Gould emphasized that the company will continue to focus on value-enhancing opportunities aimed at driving substantial long-term shareholder value, reflecting confidence in the potential of future market opportunities.
- Diversified Portfolio: As of December 17, 2025, BRT owns or has interests in 31 multi-family properties with 8,311 units, demonstrating its ongoing expansion in diversified investments and market coverage.
See More
BRT Apartments Corp. Finalizes Debt Refinancing Deals
Refinancing Details: BRT Apartments Corp. has refinanced three maturing mortgages totaling $42.7 million, replacing them with new debt of approximately $71.9 million at a higher interest rate of 4.95% and a remaining term of about nine years.
Financial Strategy: The company utilized $17.5 million from the refinancing proceeds to pay off its credit facility, positioning itself to pursue future investment opportunities in core Sunbelt markets.
Company Overview: BRT is a real estate investment trust that owns and operates multi-family properties, currently holding interests in 31 properties with a total of 8,311 units across 11 states.
Leadership Statement: CEO Jeffrey A. Gould emphasized the company's focus on value-enhancing opportunities to drive long-term shareholder value following the successful refinancing.
See More
Bioretec Updates Strategy for 2026-2028 with New Financial Targets
- Strategic Overhaul: Bioretec's strategy for 2026-2028 focuses on commercial performance and sales acceleration in both the U.S. and international markets, aiming for growth through ongoing R&D and expansion of the RemeOs™ product family.
- Innovation-Driven: The company is committed to establishing a competitive advantage through leading materials science and clinical evidence generation, with the goal of becoming a recognized player in the global orthopedic market, particularly in absorbable metal implants by the end of the strategy period.
- Financial Targets: Despite planned strategic investments in R&D and commercialization, Bioretec does not expect to achieve cash flow positivity or profitability during this period, indicating a focus on long-term growth.
- Pipeline Update: Bioretec plans to introduce a new product every 12-18 months, particularly expanding the RemeOs™ product family to meet market demand for high-performance absorbable implants, further solidifying its market position.
See More
